Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)

By Meulenbeld Hielke   Bono Johann   Tagawa Scott   Whang Young   Li Xiaoyun   Heath Karl   Zandvliet Anthe   Ebbinghaus Scot   Hudes Gary   Wit Ronald  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 909-916

Springer Publishing Company

Access to resources Recommend Favorite

Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

By Cai Zerong   Ke Jia   He Xiaosheng   Yuan Ruixue   Chen Yufeng   Wu Xianrui   Wang Lei   Wang Jianping   Lan Ping   Wu Xiaojian  

Annals of Surgical Oncology, Vol. 21, Iss. 1, 2014-01 ,pp. : 179-188

Springer Publishing Company

Access to resources Recommend Favorite

Role of mTOR inhibitor in cholangiocarcinoma cell progression

By        

Oncology Letters, Vol. 7, Iss. 3, 2014-01 ,pp. : 854-860

Spandidos Publications

Access to resources Recommend Favorite

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

By Behrens Diana   Lykkesfeldt Anne   Fichtner Iduna  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite